APOE and neoplasm: Treatment with LXR agonists leads to apoptosis of MDSCs and a reduction in tumor volume, resulting from activated transcription target apolipoprotein E (ApoE), which binds with its receptor, expressed on MDSCs, and induces MDSC depletion, ultimately inhibiting tumor growth [79,80,81].